Windlas Biotech Ltd

NSE: WINDLAS · BSE: 543329 · Pharmaceuticals & Biotechnology · 6 announcements

Share price: ₹1,102.55
Market cap: ₹2,314 Cr
Revenue (annual): ₹904.1 Cr
Net profit (annual): ₹66.44 Cr
P/E (TTM): 34.8×Sector 50.4×
Promoter holding: 63.31%+1.41% QoQ
FII holding: 2.04%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Earnings Call 2 Financial Results 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

3 announcements with these filters

14 Aug 2026 14:59 IST BSE

Earnings Call

Windlas Biotech Earnings Call Transcript: Key Takeaways

Windlas Biotech reported record quarterly revenue driven by 29% growth in CDMO vertical. Management focuses on operational excellence and capacity expansion via Plant 6 commercialization.

Open call summary → Read the filing ↗

10 Aug 2026 16:05 IST NSE

Earnings Call

Windlas Biotech Investor Presentation: Key Takeaways

Windlas Biotech reported Q1FY27 revenue of ₹248 Cr (18% YoY). Adjusted EBITDA and PAT grew 26% and 37% respectively, excluding ESOP costs, driven by CDMO expansion.

Open call summary → Read the filing ↗

10 Aug 2026 15:24 IST BSE

Financial Results

Windlas Biotech Q1 FY27 Results: Net Profit ₹17.7 Cr, Up 0.0% YoY

Windlas Biotech Ltd reported revenue from operations of ₹248.1 Cr (+18.1% YoY) and net profit of ₹17.7 Cr (+0.0% YoY) for Q1 FY27.

Key figure: Net profit ₹17.7 Cr · +0.0% YoY

Open full results → Read the filing ↗